Sepsis in burns: A review of current practice and future therapies

Annals of Plastic Surgery

Volumn 65, Issue 2, 2010, Pages 228-236

  Chipp, Elizabeth ^a   Milner, Christopher S ^b   Blackburn, Adam V ^c  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY HOSPITAL OF NORTH DURHAM   (United Kingdom)

Author keywords

antibiotics; burns; guidelines; sepsis; toxic shock syndrome

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; INSULIN; PROTEIN C;

ANTIBIOTIC PROPHYLAXIS; BANDAGE; BURN; CENTRAL VENOUS CATHETERIZATION; HUMAN; REVIEW; SEPSIS; WASTE MANAGEMENT;

ANTI-INFLAMMATORY AGENTS; ANTIBIOTIC PROPHYLAXIS; BANDAGES; BIOLOGICAL MARKERS; BURNS; CATHETERIZATION, CENTRAL VENOUS; DECONTAMINATION; HUMANS; INSULIN; PROTEIN C; SEPSIS;

EID: 77955230366     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/SAP.0b013e3181c9c35c     Document Type: Article

References (115)

1. Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care. 2006;10:R42.
2. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-874.
3. Levy MM, Fink MP, Marshall JC, et al. 2001 CCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference. Intensive Care Med. 2003;29: 530-538. (Pubitemid 36523666)
4. Atiyeh BS, Gunn SW, Dibo SA. Metabolic implications of severe burn injuries and their management: a systematic review of the literature. World J Surg. 2008;32:1857-1869.
5. Greenhalgh DG, Saffle JR, Holmes JH, et al. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res. 2007;28:776-790.
6. Janzekovic Z. A new concept in early excision and grafting of burns. J Trauma. 1970;10:1103-1108.
7. Ong YS, Samuel M, Song C. Meta-analysis of early excision of burns. Burns. 2006;32:145-150. (Pubitemid 43197648)
8. Subrahmanyam M. Early tangential excision and skin grafting of moderate burns is superior to honey dressing: a prospective randomised trial. Burns 1999;25:729-731.
9. Atiyeh BS, Costagliola M, Hayek SN, et al. Effect of silver on burn wound infection control and healing: review of the literature. Burns. 2007;33:139-148. (Pubitemid 46188672)
10. Atiyeh BS, Hayek SN, Gunn SW. New technologies for burn wound closure and healing-review of the literature. Burns. 2005;31:944-956.
11. McAllister RMR, Mercer MSG, Mercer BDG, et al. Early diagnosis of staphylococcal toxaemia in burned children. Burns. 1993;19:22-25. (Pubitemid 23059385)
12. Rashid A, Brown A, Khan K. On the use of prophylactic antibiotics in prevention of toxic shock syndrome. Burns. 2005;31:981-985. (Pubitemid 41676859)
13. Edwards-Jones V, Dawson MM, Childs C. A survey into toxic shock syndrome (TSS) in UK burns units. Burns. 2000;26:323-333. (Pubitemid 30181120)
14. White MC, Thornton K, Young AE. Early diagnosis and treatment of toxic shock syndrome in paediatric burns. Burns. 2005;31:193-197. (Pubitemid 40430875)
15. Edwards-Jones V, Childs C, Foster HA. A comparison of phenotypic properties of isolates of S. Aureus from burned patients and other patient groups. Burns. 1996;22:384-389. (Pubitemid 26245521)
16. Young AE, Thornton KL. Toxic shock syndrome in burns: diagnosis and management. Arch Dis Child Educ Pract Ed. 2007;92:97-100.
17. Al-Benna S, Collin T, Jeffery S. A survey into the prophylaxis of toxic shock syndrome in paediatric burns units of the British Isles (abstract). Burns. 2007;33S:S151.
18. Burd A. Toxic shock syndrome in paediatric burns: a peculiarly British malady or malady of peculiar British? Burns. 2005;31:937-938. (Pubitemid 41394161)
19. Vloemans AF, Gorissen KJ. Non existence of toxic shock syndrome in Dutch burns centres. Burns. 2006;32:522-533.
20. Ramos GE, Bolgiani AN, Patino O, et al. Catheter infection risk related to the distance between insertion site and burned area. J Burn Care Rehabil. 2001;23:266-271. (Pubitemid 34779068)
21. Sheridan RL, Webster JM, Peterson HF, et al. Central venous catheter sepsis with weekly catheter change in paediatric patients: an analysis of 221 patients. Burns. 1995;21:127-129.
22. O'Mara MS, Reed NL, Palmieri TL, et al. Central venous catheter infections in patients with scheduled catheter exchange and replacement. J Surg Res. 2007;142:341-350. (Pubitemid 47418836)
23. Timsit JF. Scheduled replacement of central venous catheters is not necessary. Infect Control Hosp Epidemiol. 2000;21:371-374.
24. Cook D, Randolph A, Kernerman P, et al. Central venous catheter replacement strategies: a systematic review of the literature. Crit Care Med. 1997;25:1417-1424. (Pubitemid 27347310)
25. Department of Health. Saving Lives: Reducing Infection, Delivering Clean and Safe Care. High Impact Intervention No 1: Central Venous Catheter Care Bundle. Department of Health; 2007. Available at http:// www.clean-safe-care. nhs.uk/toolfiles/14-SL-HII-1-v2.pdf. Last accessed December 6, 2008.
26. Casey AL, Mermel LA, Nightingale P, et al. Antimicrobial central venous catheters in adults: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8:763-776.
27. Silvestri L, van Saene HKF, Milanese M, et al. Selective decontamination of the digestive tract reduced bacterial bloodstream infection and mortality in critically ill patients. Systematic review of randomized, controlled trials. J Hosp Infect. 2007;65:187-203. (Pubitemid 46268209)
28. Mackie DP, van Hertum WA, Schumberg T, et al. Prevention of infection in burns: preliminary experience with selective decontamination of the digestive tract in patients with extensive injuries. J Trauma. 1992;32:570-575.
29. Mackie DP, van Hertum WA, Schumberg TH, et al. Reduction in Staphylococcus aureus wound colonization using nasal mupirocin and selective decontamination of the digestive tract in extensive burns. Burns. 1994; 20(Suppl 1):S14-S17.
30. Manson WL, Klasen HJ, Sauer EW, et al. Selective intestinal decontamination for prevention of wound colonization in severely burned patients: a retrospective analysis. Burns. 1992;18:98-102.
31. Barret JP, Jeschke MG, Herndon DN. Selective decontamination of the digestive tract in severely burned paediatric patients. Burns. 2001;27:439-445. (Pubitemid 32651873)
32. De la Cal MA, Cerda E, Garcia-Hierro P, et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomised placebo-controlled, double-blind trial. Ann Surg. 2005;23: 424-430. (Pubitemid 40299718)
33. Dellinger RP, Levy MM, Carelt JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med. 2008;36:296-327.
34. Poeze M, Ramsay G, Gerlach H, et al. An international sepsis survey: a study of doctors' knowledge and perception about sepsis. Crit Care. 2004; 8:R409-R413.
35. Groarke JD, Gallagher J, Stack J, et al. Use of an admission early warning score to predict patient morbidity and mortality and treatment success. Emerg Med J. 2008;25:803-806.
36. Gardner-Thorpe J, Love N, Wrightson J, et al. The value of Modified Early Warning Score (MEWS) in surgical in-patients: a prospective observational study. Ann R Coll Surg Engl. 2006;88:571-575. (Pubitemid 44596464)
37. Subbe CP, Davies RG, Williams E, et al. Effect of introducing the Modified Early Warning Score on clinical outcomes, cardio-pulmonary arrests and intensive care utilisation in acute medical admissions. Anaesthesia. 2003; 58:797-802. (Pubitemid 36934576)
38. Zhang B, Huang H, Chen Y, et al. Plasma tumour necrosis factor-alpha, its soluble receptors and interleukin-1 beta levels in critically burned patients. Burns. 1998;24:599-603. (Pubitemid 29002576)
39. Dehne MG, Sablotzki A, Hoffmann A, et al. Alterations of acute phase reaction and cytokine production in patients following severe burn injury. Burns. 2002;28:535-542. (Pubitemid 36153197)
40. Infanger M, Schmidt O, Kossmehl P, et al. Vascular endothelial growth factor serum level is strongly enhanced after burn injury and correlated with local and general tissue oedema. Burns. 2004;30:305-311. (Pubitemid 38622441)
41. Uzzan B, Cohen R, Nicholas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006;34:1996-2003. (Pubitemid 43982479)
42. Von Heimburg D, Stieghorst W, Khorram-Sefat R, et al. Procalcitonin - a sepsis parameter in severe burn injuries. Burns. 1998;24:745-750. (Pubitemid 29022845)
43. Bargues L, Chancerelle Y, Catineau J, et al. Evaluation of serum procalcitonin in the ICU following severe burn. Burns. 2007;33:860-864. (Pubitemid 47374355)
44. Barati M, Alinejad F, Bahar MA, et al. Comparison of WBC, ESR, CRP and PCT serum levels in septic and non-septic burn cases. Burns. 2008;34:770-774.
45. Lavrentieva A, Kontakiotis T, Lazaridis L, et al. Inflammatory markers in patients with severe burn injury. What is the best indicator of sepsis? Burns. 2007;33:189-194. (Pubitemid 46201864)
46. Neely AN, Fowler LA, Kagan RJ, et al. Procalcitonin in paediatric burn patients: an early indicator of sepsis? J Burn Care Rehabil. 2004;25:76-80.
47. Steer JA, Papini RPG, Wilson APR, et al. Quantitative microbiology in the management of burns patients. I. Correlation between quantitative and qualitative burn wound biopsy culture and surface alginate swab culture. Burns. 1996;22:173-176.
48. Uppal SK, Ram S, Kwatra B, et al. Comparative evaluation of surface wound and quantitative full thickness wound biopsy culture in burn patients. Burns. 2007;33:460-463. (Pubitemid 46702387)
49. Basak S, Dutta SK, Gupta S, et al. Bacteriology of wound infection: evaluation by surface swab and quantitative full thickness wound biopsy culture. J Ind Med Assoc. 1992;90:33-35.
50. Steer JA, Papini RPG, Wilson APR, et al. Quantitative microbiology in the management of burns patients. II. Relationship between bacterial counts obtained by burn wound biopsy culture and surface alginate swab culture, with clinical outcome following burn surgery and change of dressings. Burns. 1996;22:177-181. (Pubitemid 126334290)
51. Sheridan RL, Ryan CM, Yin LM, et al. Death in the burn unit: sterile multiple organ failure. Burns. 1998;24:307-311.
52. Schwacha MG. Macrophages and post-burn immune dysfunction. Burns. 2003;29:1-14.
53. Chen J, Zhou YP, Rong XZ. An experimental study on systemic inflammatory response syndrome induced by subeschar fluid. Burns. 2000;26:149-155.
54. Huang Q, Xu W, Ustinova E, et al. Myosin light chain kinase-dependent microvascular hyperpermeability in thermal injury. Shock. 2003;20:363-368.
55. Maekawa T, Kajihara H, Okabayashi K, et al. Impairment of splenic B and T cell lymphocytes in the early period after severe thermal injury: immunohistochemical and electron microscope analysis. Burns. 2002;28:329-339. (Pubitemid 34621356)
56. Cole RP, Shakespeare PG. Toxic shock syndrome in scalded children. Burns. 1990;16:221-224. (Pubitemid 20292975)
57. Childs C, Edwards-Jones V, Dawson M, et al. Toxic shock syndrome toxin-1 (TSST-1) antibody levels in burned children. Burns. 1999;25:473-476. (Pubitemid 29433537)
58. Schlievert PM, Kelly JA. Clindamycin induced suppression of toxic shock syndrome associated exotoxin production. J Infect Dis. 1984;149:471-474.
59. Edwards-Jones V, Foster HA. The effect of topical antimicrobial agents on the production of toxic shock syndrome toxin-1 toxin. J Med Microbiol. 1994;41:505-509. (Pubitemid 24374125)
60. Andrews MM, Giacobbe KD, Parsonnet J. Induction of toxics shock syndrome toxin-1 (TSST-1) and beta-lactamase by subinhibitory concentrations of beta-lactam antibiotics (abstract). In: Biomedicine; May 3-6, 1996; Washington, DC. N-IN-0011.
61. Nakazawa H, Nozaki M, Shimoda K, et al. Successful management using combination therapy of endotoxin absorption therapy (PMX) and continuous hemodiafiltration (CVVHDF) of a critically ill burn patient suffering from methicillin-resistant Staphylococcus aureus toxic shock syndrome. Burns. 2008;34:288-291. (Pubitemid 351163441)
62. Horvath EE, Murray CK, Vaughan GM, et al. Fungal wound infection (not colonisation) is independently associated with mortality in burns patients. Ann Surg. 2007;245:978-985.
63. Trottier V, Segura PG, Namias N, et al. Outcomes of Acinetobacter baumannii infection in critically ill burned patients. J Burn Care Res. 2007;28: 248-254. (Pubitemid 46411561)
64. Conil JM, Georges B, Lavit M, et al. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance. Int J Clin Pharmacol Ther. 2007;45:529-538. (Pubitemid 47527452)
65. Roberts JA, Lipman J, Blot S, et al. Better outcomes through continuous infusions of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care. 2008;14:390-396.
66. Lovering AM, Le Froch R, Hovsepian L, et al. Pharmacokinetic evaluation of linezolid in patients with major thermal injuries. J Antimicrob Chemother. 2009;63:553-559.
67. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta analysis. Crit Care Med. 1995;23:1294-1303.
68. Annane D, Bellisant E, Bollaert PE, et al. Corticosteroids for treating severe sepsis and septic shock. Cochrane Database Syst Rev. 2004;1:CD002243.
69. Cronin L, Cook DJ, Carelt J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med. 1995; 23:1430-1439.
70. Fuchs P, Bozkurt A, Johnen D, et al. Beneficial effects of corticosteroids in catecholamine-dependent septic burn patients. Burns. 2007;33:306-311. (Pubitemid 46428494)
71. Winter W, Kamolz L, Donner A, et al. Hydrocortisone improved haemodynamics and fluid requirement in surviving but not non-surviving of severely burned patients. Burns. 2003;29:717-720. (Pubitemid 37230089)
72. Levi M, van der Poll T. Recombinant human activated protein C: current insights into its mechanism of action. Crit Care. 2007;11:S3. (Pubitemid 351851018)
73. Bernard GR, Vincent J, Laterre P, et al. For the recombinant human activated Protein C worldwide evaluation in severe sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated Protein C for severe sepsis. N Engl J Med. 2001;34:699-709.
74. Rowan KM, Welch CA, North E, et al. Drotrecogin alpha (activated): real life use and outcomes for the UK. Crit Care. 2008;12:R58. (Pubitemid 351722569)
75. Vincent JL, Bernard GR, Beale R, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety an implications for early treatment. Crit Care Med. 2005;33:2266-2277. (Pubitemid 41437481)
76. Laterre PF. Clinical trials in severe sepsis with drotrecogin alfa (activated). Crit Care. 2007;11:S5.
77. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adult patients with severe sepsis and a low risk of death. N Engl J Med. 2005;353:1332-1341. (Pubitemid 41362701)
78. Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomised controlled trial. Lancet. 2007;369:836-843. (Pubitemid 46365900)
79. Weintraub J, Satterwhite T, Allo M. The use of drotrecogin alfa recombinant activated protein C for severe sepsis in the critically burned patient: a new treatment approach. Burns. 2006;32:783-787. (Pubitemid 44293065)
80. Brunsvold ME, Arbabi S, Dimo M, et al. Drotrecogin alfa in patients with burns and soft tissue injury. J Burn Care Res. 2008;29:676-678.
81. Van Den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-1367.
82. Van Den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449-461. (Pubitemid 43200296)
83. Holm C, Horbrand F, Mary M, et al. Acute hyperglycaemia following thermal injury: friend or foe? Resuscitation. 2004;60:71-77. (Pubitemid 38251230)
84. Van Den Berghe G, Wilmer A, Milants I, et al. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes. 2006;55:3151-3159. (Pubitemid 44923655)
85. Mowlavi A, Andrews K, Milner S, et al. The effects of hyperglycaemia on skin graft survival in the burn patient. Ann Plast Surg. 2000;45:629-632.
86. Gore DC, Chinkes DL, Hart DW, et al. Hyperglycaemia exacerbates muscle protein catabolism in burn-injured patients. Crit Care Med. 2002;30:2438-2442.
87. Gore DC, Chinkes D, Heggers J, et al. Association of hyperglycaemia with increased mortality after severe burn injury. J Trauma. 2001;51:540-544. (Pubitemid 33009642)
88. Gauglitz GG, Herndon DN, Jeschke MG. Insulin resistance postburn: underlying mechanisms and current therapeutic strategies. J Burn Care Res. 2008;29:683-694.
89. Gore DC, Wolf SE, Herndon DN, et al. Metformin blunts stress induced hyperglycaemia after thermal injury. J Trauma. 2003;54:555-561.
90. Ipaktchi K, Mattar A, Niederbichler AD, et al. Attenuating burn wound inflammatory signalling reduces systemic inflammation and acute lung injury. J Immunol. 2006;177:8065-8071. (Pubitemid 44846324)
91. Bone RC. Sir Isaac Newton, sepsis, SIRS and CARS. Crit Care Med. 1996;24:1125-1128.
92. Herndon DN, Traber DL. Pulmonary circulation and burns and trauma. J Trauma. 1990;30(12 Suppl):S41-S44.
93. Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU group for Severe Sepsis. JAMA. 1995;274:968-974.
94. Rangel-Frausto MS, Pittet D, Costigan M, et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995;273:117-123.
95. McCloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-IA. A randomized, double-blind, placebocontrolled trial. CHESS Trial Study Group. Ann Intern Med. 1994;121:1-5.
96. De Maio A, Torres MB, Reeves RH. Genetic determinants influencing the response to injury, inflammation and sepsis. Shock. 2005;23:11-17. (Pubitemid 40089520)
97. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003;101:3765-3767.
98. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med. 2003;9:517-524.
99. Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 1994;271:1836-1843. (Pubitemid 24169697)
100. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med. 2001;29(7 Suppl): S121-S125. (Pubitemid 32681594)
101. Stevens T, Rosenberg R, Aird W, et al. NHLBI workshop report: endothelial cell phenotypes in heart, lung and blood diseases. Am J Physiol Cell Physiol. 2001;281:C1422-C1433. (Pubitemid 33121665)
102. Mantovani A, Sozzani S, Introna M. Endothelial activation by cytokines. Ann N Y Acad Sci. 1997;832:93-116. (Pubitemid 28045307)
103. Szabo C, Southan GJ, Thiemermann C. Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulphate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci USA. 1994;91:12472-12476.
104. Badger AM, Bradbeer JN, Votta B, et al. Pharmacological profile of SB203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther. 1996;279:1453-1461. (Pubitemid 27166795)
105. Liu SF, Ye X, Malik AB. Inhibition of NF-kappa B activation by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes. Circulation. 1999;100:1330-1337. (Pubitemid 29440127)
106. Rahman A, Anwar KN, Malik AB. Protein kinase C-zeta mediates TNFalpha- induced ICAM-1 gene transcription in endothelial cells. Am J Physiol Cell Physiol. 2000;279:C906-C914.
107. Rahman A, Anwar KN, Uddin S, et al. Protein kinase C-delta regulates thrombin-induced ICAM-1 gene expression in endothelial cells via activation of p38 mitogen-activated protein kinase. Mol Cell Biol. 2001;21:5554-5565. (Pubitemid 32702459)
108. Branger J, Van Den Blink B, Weijer S, et al. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxaemia. J Immunol. 2002;168:4070-4077. (Pubitemid 34298414)
109. Zeng W, Matter WF, Yan SB, et al. Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signalling. Crit Care Med. 2004;32(5 Suppl):S302-S308.
110. Finigan JH, Dudek SM, Singleton PA, et al. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem. 2005;280:17286-17293.
111. Feistritzer C, Schuepach RA, Mosnier LO, et al. Protective signalling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem. 2006;281:20077-20084. (Pubitemid 44065782)
112. Mizutani A, Okajima K, Uchiba M, et al. Activated protein C reduces ischaemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood. 2000;95:3781-3787. (Pubitemid 30412850)
113. Brindle NP, Saharinen P, Alitalo K. Signalling and functions of angiopoietin- 1 in vascular protection. Circ Res. 2006;98:1014-1023. (Pubitemid 43755222)
114. Vlachou E, Gosling P, Moiemen NS. Microalbuminuria: a marker of endothelial dysfunction in thermal injury. Burns. 2006;32:1009-1016. (Pubitemid 44647541)
115. Vlachou E, Gosling P, Moiemen NS. Microalbuminuria: a marker of systemic endothelial dysfunction during burn excision. Burns. 2008;34: 241-245. (Pubitemid 351163451)